Fully Human Antibody / TCR Platforms

Bispecific Antibody Platform

Bispecific antibodies (BsAbs) offer unique advantages by targeting two antigens simultaneously, enabling enhanced specificity, overcoming resistance, and addressing disease heterogeneity. They optimize pharmacokinetics, reduce off-target effects, and support diverse mechanisms such as pathway blockade and immune cell redirection, unlocking broad therapeutic potential.

• The ability to simultaneously target multiple tumor-driven proteins, potentially overcoming drug resistance.
• Recognition of cells co-expressing both targets to increase tumor specificity and reduce off-target toxicity.
• The combination of two selected targets increases internalization and thus tumor killing.

• 10+

  Fully-human BsAbs

• 10+

  TCR-mimic Assets